10 Critical Questions For LIS Vendor Evaluation

The LIS you choose today will directly impact your lab’s efficiency, compliance, and scalability for years to come. Yet, many evaluation processes fall short, focusing heavily on demos and pricing while overlooking critical risks tied to implementation, integration, data migration, and long-term costs.

This blog outlines 10 essential questions that experienced lab leaders use to evaluate LIS vendors more effectively. For each, it highlights what strong, credible answers look like and the red flags that should immediately disqualify a vendor. Used correctly, this framework helps lab directors, IT leaders, and procurement teams move beyond surface-level comparisons and make confident, future-proof decisions during their LIS vendor evaluation process.

The 10 Questions For LIS Vendor You Must Ask Before Signing – With Disqualifying Answer Flags

Question 1: What is your average implementation timeline for a lab of our size and complexity, and what are the most common causes of delays?

Implementation timelines are among the most misrepresented aspects of an LIS vendor evaluation, yet they directly impact revenue continuity, staff productivity, and patient service levels. For context, a single-site lab may go live in 8–12 weeks, while multi-location or multi-modality labs typically require 12–24+ weeks, depending on integrations, data migration scope, and internal readiness.

Good answer:

A credible vendor will anchor their response in real project experience, not estimates. They should:

• Provide a clear timeline range based on labs similar in size, test volume, and complexity
• Break down the implementation into phases such as requirement mapping, configuration, integrations, validation, and go-live
• Proactively identify common delay factors, including:
  • Data migration complexity (inconsistent legacy data, mapping challenges)
  • Instrument interface queues (dependency on third-party vendors or custom builds)
  • Internal team availability (limited bandwidth for UAT, training, and validation)
• Most importantly, explain how they mitigate these risks, such as parallel data validation, dedicated interface teams, and structured project governance with defined milestones

Disqualifying answer:

• Generic responses like “it depends” without context or benchmarks
• Overly aggressive timelines that ignore your operational scale (e.g., committing to a 4-week go-live for a multi-center lab)
• No acknowledgment of real-world bottlenecks or risk factors

A vendor who cannot provide a realistic, experience-backed timeline is unlikely to deliver a predictable implementation.

Question 2: How many active instrument interfaces do you support, and what is your SLA for building a net-new interface for an analyzer we use that isn’t on your standard list?

Instrument integration is a core component of lab automation, and one of the most common failure points in LIS implementations. Most mid-to-large labs operate with 10–50+ analyzers, and even a few missing or unstable interfaces can lead to 20–30% higher manual intervention, increasing turnaround time and error risk.

Good answer:

A mature LIS vendor will demonstrate both depth (number of integrations) and process maturity (how they build new ones). Look for:

• A specific number of active, production-grade interfaces (e.g., 150–300+), not just “supported” instruments
• Confirmation of experience with analyzers similar to yours (same manufacturer or communication standards)
• A clearly defined SLA for new interface development, typically:
  • 4–8 weeks for ASTM/HL7 bidirectional integrations
  • Structured phases including protocol mapping, development, validation, and testing
• Clarity on their integration architecture (direct LIS integration, middleware support, API-based connectivity)
• A defined process for ongoing maintenance and troubleshooting

Disqualifying answer:

• Broad, non-committal statements like “we integrate with most instruments”
• No concrete number of active interfaces or real-world deployments
• Inability to confirm compatibility with your analyzers before contract signing
• No defined SLA or process for building new interfaces

Integration capabilities don’t just affect go-live; they define how efficiently your lab operates every single day.

Question 3: Show me your audit trail for a specific sample result change. Who changed it, when, what was the old value, and why, and can a CAP inspector pull that report in under 5 minutes?

Audit trails are a critical requirement for accreditation and regulatory compliance. Whether it’s CAP, ISO 15189, or other standards, labs are expected to maintain complete traceability of every data change—and be able to retrieve it quickly during inspections. In real audit scenarios, teams are often given just a few minutes to produce this evidence.

Good answer:

A credible LIS vendor will not just describe this capability; they will demonstrate it live during the demo. Look for:

• A real-time audit trail showing:
  • User identity (who made the change)
  • Timestamp (when it occurred)
  • Previous vs updated value
  • Reason for modification
• Logs that are immutable (cannot be altered) and automatically recorded
• A human-readable interface, not raw technical data
• Ability to filter, search, and export logs instantly
• Alignment with ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus completeness and consistency)

Disqualifying answer:

• Inability to demonstrate the audit trail during the demo
• Statements like “we can extract that from the database if needed”
• Reliance on backend or engineering intervention to generate audit logs
• Logs that are incomplete, hard to interpret, or not easily accessible

If audit data cannot be accessed instantly and independently by your lab team, it creates a serious compliance risk during inspections.

Question 4: What is your uptime SLA, how is downtime calculated, and what are the remedies if you breach it?

System availability is critical in laboratory operations where even short outages can delay hundreds of test results and disrupt clinical workflows. The difference between 99.5% and 99.9% uptime may seem small, but it translates to over 3.5 additional hours of downtime per month, which can significantly impact high-volume labs.

Good answer:

A reliable LIS vendor will provide clear, contractual commitments, not just general assurances. Look for:

• A defined uptime SLA of 99.9% or higher, backed by monitoring and reporting
• A precise explanation of how uptime is calculated, including:
  • Whether scheduled maintenance windows are included or excluded
  • How partial outages or degraded performance are treated
• Transparency into monitoring tools and reporting frequency
• Clearly defined remedies for SLA breaches, such as service credits, financial penalties, or extended support coverage
• Defined incident response and resolution timelines

Disqualifying answer:

• Vague statements like “we have excellent uptime” without a written SLA
• SLAs that exclude maintenance windows (where most downtime typically occurs)
• No measurable definition of downtime or lack of reporting transparency
• Absence of penalties or accountability if SLA commitments are not met

Without a clearly defined and enforceable SLA, uptime becomes a claim—not a guarantee—and your lab bears the operational risk.

Question 5: What does your data migration process look like, and what is the contractual commitment for migrating our historical patient data?

Data migration is one of the most critical and highest-risk components of any LIS implementation. Most labs carry 5–10+ years of patient history, including reports, reference ranges, and audit logs. Any gaps or inaccuracies can impact clinical continuity, compliance, and medico-legal traceability.

Good answer:

A reliable LIS vendor will present a structured, repeatable migration framework, not an ad hoc process. Look for:

• A clearly defined methodology covering:
  • Data extraction from the legacy system
  • Field mapping and normalization (aligning formats, units, reference ranges)
  • Data transformation and validation
  • Reconciliation and sign-off before go-live
• Early sharing of data format specifications and templates so your team knows what is required
• Inclusion of migration within the core contract scope, not as an afterthought
• Clearly defined acceptance criteria, such as data completeness thresholds and validation checkpoints
• Demonstrated experience migrating from systems similar to your current LIS
• Support for parallel run or phased validation to minimize operational risk

Disqualifying answer:

• Migration positioned as a separate professional services engagement priced after contract signing
• Lack of a defined methodology or reliance on manual processes
• No prior experience with your existing LIS or similar systems
• Absence of validation, reconciliation, or acceptance criteria

Data migration isn’t just a technical step; it’s a continuity and compliance requirement. If it’s not clearly defined and contractually committed, the risk shifts entirely to your lab.

Question 6: What are your pricing escalation terms at annual renewal?

Initial pricing often looks competitive—but the total cost of ownership over 3–5 years is where many labs lose control of budgets. Without defined escalation terms, LIS costs can increase by 20–40% over the contract period, especially when renewal pricing is left open-ended.

Good answer:

A transparent vendor will clearly define how pricing evolves over time and ensure it is contractually enforceable. Look for:

• Fixed annual escalation (e.g., 3–5%) or increases tied to a standard index like CPI
• Full visibility into all cost components, including licenses, integrations, support, and upgrades
• Clear differentiation between one-time vs recurring costs
• Written confirmation that escalation terms apply consistently across renewals—not renegotiated arbitrarily
• No hidden dependencies that could trigger additional charges later

Disqualifying answer:

• Vague statements like “pricing is reviewed annually” with no defined cap
• Absence of written escalation terms in the contract
• Flexibility that allows the vendor to adjust pricing unilaterally at renewal
• Lack of transparency around what drives cost changes

The real financial impact of an LIS is rarely in year one—it shows up at renewal. If escalation isn’t clearly defined, your costs are effectively uncontrolled.

Question 7: Can you provide three customer references at labs of similar size and modality mix, and can we speak with their IT director specifically?

Customer references are one of the most reliable ways to validate a vendor’s real-world performance. Labs with similar volumes, modalities, and operational complexity will surface insights that demos and sales conversations often miss—especially around implementation challenges, day-to-day usability, and post-go-live support.

Good answer:

A confident and transparent vendor will:

• Proactively provide multiple references (at least 3) from labs comparable to yours in size, workload, and modality mix
• Offer access to IT leaders, lab managers, or operations heads—the people who actively use and manage the system
• Avoid over-curating conversations, allowing for open and candid discussions
• Share context on each reference, such as implementation scope, integrations, and outcomes

This level of transparency indicates the LIS vendor has consistent delivery capability across similar environments, not just isolated success stories.

Disqualifying answer:

• Limited references or inability to provide labs similar to yours
• Restricting conversations to executive-level stakeholders only, who may not be involved in daily system use
• Heavily controlled or scripted interactions
• References from labs that are significantly smaller, less complex, or not comparable to your setup

The real test of a vendor isn’t what they present; it’s what their customers experience after go-live.

Question 8: What happens to our data if we decide to leave at contract end? What format is it delivered in, at what cost, and within what timeframe?

Data ownership and portability are often overlooked during LIS vendor evaluation, but they become critical at contract exit. Labs generate and rely on years of patient records, reports, and audit logs, and any friction in accessing this data can disrupt continuity of care, compliance, and future system transitions.

Good answer:

A transparent vendor will treat data portability as a standard right—not an exception. Look for:

• Data delivered in vendor-neutral, widely usable formats such as HL7, CSV, or FHIR-compatible structures
• Clear documentation of data schemas and structure to support migration into a new system
• Inclusion of data export within the standard contract terms, not as an additional service
• A defined timeline for delivery (e.g., within 2–6 weeks of contract termination)
• Assurance that complete datasets are included—patient history, reports, audit trails, and metadata

Disqualifying answer:

• Positioning data export as a custom or chargeable engagement at the time of exit
• Providing data in proprietary or encrypted formats that require vendor-specific tools to access
• No clear timeline or partial data access
• Lack of clarity on what data will actually be included

Your lab’s data is a long-term asset. If access to it is restricted or costly at exit, you’re effectively locked into the vendor.

Question 9: Walk me through your HIPAA compliance architecture; where is PHI stored, who can access it, and how would we be notified in the event of a breach?

Data security is a foundational requirement in any LIS decision. Healthcare data breaches are among the most costly, with the average incident exceeding $10 million globally, and labs are increasingly expected to demonstrate strong controls around data protection, access, and incident response—whether under HIPAA, ISO 27001, or regional regulations.

Good answer:

A credible vendor will provide clear, structured, and documented security practices, not high-level assurances. Look for:

• A defined compliance framework (e.g., HIPAA, ISO, SOC 2), along with Business Associate Agreement (BAA) clarity where applicable
• Explicit details on data storage and residency (where patient data is hosted and governed)
• Strong encryption standards, such as:
  • AES-256 for data at rest
  • TLS 1.2/1.3 for data in transit
  • Robust role-based access controls (RBAC) and user authentication mechanisms
• Continuous monitoring, logging, and auditability of access to patient data
• A clearly defined incident response plan, including:
  • Breach detection and containment processes
  • Notification timelines and escalation protocols
  • Support provided to the lab during and after an incident

Disqualifying answer:

• Vague or incomplete responses about security architecture
• Reluctance to share compliance documentation or agreements before contract signing
• Inability to confirm where data is stored or who has access to it
• No defined breach response process or unclear notification timelines

Security is not just about technology; it reflects the vendor’s overall maturity. If they cannot explain it clearly, they are unlikely to manage it effectively.

Question 10: What is on your product roadmap for the next 18 months, and how do customer-requested features get prioritized?

LIS is not a one-time implementation; it’s a long-term platform that must evolve with changing lab needs, regulatory requirements, and technology advancements. Labs that operate on stagnant systems often experience reduced efficiency, limited automation, and growing integration gaps over time.

Good answer:

A forward-looking vendor will demonstrate both product vision and execution capability. Look for:

• A high-level, shareable roadmap outlining planned enhancements (e.g., automation, analytics, interoperability, AI-driven workflows)
• A clear explanation of how customer feedback is captured and prioritized, such as:
  • User councils or advisory boards
  • Feature request tracking and voting systems
  • Regular product feedback loops
• Evidence of consistent delivery, including examples of customer-requested features released in the past 6–12 months
• A balanced roadmap that includes both innovation and ongoing product stability/improvements

Disqualifying answer:

• Refusal to share roadmap visibility, citing it as “confidential”
• Lack of a structured process for incorporating customer feedback
• Roadmap dominated by internal platform rebuilds or migrations, leaving little room for new feature development
• No recent track record of meaningful product updates

A vendor’s roadmap reflects their long-term commitment. If innovation is unclear or deprioritized, your lab risks being locked into a system that cannot keep pace with future demands.

How to Use This Framework in a Vendor Evaluation Process

The Evaluation Process Architecture

A structured LIS vendor evaluation process helps you move beyond surface-level comparisons and focus on what truly impacts long-term success—implementation, scalability, and risk.

Round 1: Discovery Call — Test Clarity Early

Start by asking all 10 questions upfront. This stage is about evaluating how clearly and confidently a vendor can respond based on real experience.

Strong vendors will provide specific, contextual answers and highlight potential challenges. Weak ones tend to stay vague or overpromise.

If a vendor lacks clarity here, they’re unlikely to improve later.

Round 2: Demo Validation — Prove the Claims

Use the demo to validate—not explore. Focus on critical areas like:

• Audit trails (Q3)
• Uptime monitoring (Q4)
• Data migration workflows (Q5)

Ask for scenario-based demonstrations aligned with your lab processes.

If they can’t show it, it’s not ready for real-world use.

Round 3: Reference Validation — Hear From Real Users

Speak directly with labs similar to yours, especially IT and operations teams. Focus on:

• Implementation experience
• Support responsiveness
• Unexpected challenges

This is where you uncover the gap between promise and reality.

Round 4: Contract & Legal Review — Lock in Commitments

Ensure all key commitments are reflected in the contract, including:

• SLA terms
• Pricing and escalation clauses
• Data ownership and exit terms

Most long-term risks surface here; if it’s not in the contract, it doesn’t exist.

Following this approach turns your LIS vendor checklist into a practical decision-making framework—helping you choose a vendor that delivers beyond the demo.

Conclusion

Choosing the right LIS is less about who delivers the most impressive demo and more about who can consistently deliver on promises over time. The gaps that lead to implementation delays, hidden costs, or compliance risks are rarely accidental—they stem from questions that were never asked or answers that were never validated. By using this structured evaluation framework, labs can shift from reactive decision-making to a more informed, risk-aware approach—ensuring the LIS they choose today continues to support operational efficiency, regulatory needs, and growth well into the future.